Inventor
HUNT CHARLEEN
US10 patents
Patents
10 patentsUS11519004B2Dec 6, 2022
Transcription modulation in animals using CRISPR/Cas systems
REGENERON PHARMA4 citations71
US12529072B2Jan 20, 2026
Transcription modulation in animals using CRISPR/CAS systems
REGENERON PHARMA0 citations61
US11730150B2Aug 22, 2023
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
REGENERON PHARMA0 citations61
US11021719B2Jun 1, 2021
Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
REGENERON PHARMA1 citations61
US10548302B2Feb 4, 2020
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
REGENERON PHARMA1 citations61
US11866794B2Jan 9, 2024
Cas-ready mouse embryonic stem cells and mice and uses thereof
REGENERON PHARMA0 citations59
US11470828B2Oct 18, 2022
Rodent model of mood disorders
REGENERON PHARMA1 citations59
US11130999B2Sep 28, 2021
Cas-ready mouse embryonic stem cells and mice and uses thereof
REGENERON PHARMA1 citations59
US12521451B2Jan 13, 2026
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
REGENERON PHARMA0 citations51
US12582104B2Mar 24, 2026
Mutant myocilin disease model and uses thereof
REGENERON PHARMA0 citations50